Cargando…
FDA authorized molecular point-of-care SARS-CoV-2 tests: A critical review on principles, systems and clinical performances
Since the start of the COVID-19 pandemic, 10 manufacturers of molecular tests for SARS-CoV-2 have received Emergency Use Authorizations from the U.S. Food and Drug Administration for point-of-care or over the counter use. In this review, the working principle of these tests is described as well as t...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Author(s). Published by Elsevier B.V.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9122839/ https://www.ncbi.nlm.nih.gov/pubmed/35619623 http://dx.doi.org/10.1016/j.biosx.2022.100158 |
_version_ | 1784711431079329792 |
---|---|
author | Bruijns, Brigitte Folkertsma, Laura Tiggelaar, Roald |
author_facet | Bruijns, Brigitte Folkertsma, Laura Tiggelaar, Roald |
author_sort | Bruijns, Brigitte |
collection | PubMed |
description | Since the start of the COVID-19 pandemic, 10 manufacturers of molecular tests for SARS-CoV-2 have received Emergency Use Authorizations from the U.S. Food and Drug Administration for point-of-care or over the counter use. In this review, the working principle of these tests is described as well as the relevant characteristics (e.g. time-to-result and specimen type). The analytical (e.g. analytical sensitivity) and clinical performance (positive and negative percent agreement) and useability characteristics (e.g. cost, reusability and throughput) of these tests are compared and critically reviewed. Also details for relevant respiratory multiplex assays of these 10 manufacturers are discussed. Critical review of scientific literature on these authorized tests revealed that for many of these tests publications are almost or completely absent, with the exception of two systems. The Xpert Xpress has been thoroughly investigated and good performance has been reported, whereas ID NOW is also well-represented in literature, but has relatively low sensitivity. |
format | Online Article Text |
id | pubmed-9122839 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | The Author(s). Published by Elsevier B.V. |
record_format | MEDLINE/PubMed |
spelling | pubmed-91228392022-05-21 FDA authorized molecular point-of-care SARS-CoV-2 tests: A critical review on principles, systems and clinical performances Bruijns, Brigitte Folkertsma, Laura Tiggelaar, Roald Biosens Bioelectron X Article Since the start of the COVID-19 pandemic, 10 manufacturers of molecular tests for SARS-CoV-2 have received Emergency Use Authorizations from the U.S. Food and Drug Administration for point-of-care or over the counter use. In this review, the working principle of these tests is described as well as the relevant characteristics (e.g. time-to-result and specimen type). The analytical (e.g. analytical sensitivity) and clinical performance (positive and negative percent agreement) and useability characteristics (e.g. cost, reusability and throughput) of these tests are compared and critically reviewed. Also details for relevant respiratory multiplex assays of these 10 manufacturers are discussed. Critical review of scientific literature on these authorized tests revealed that for many of these tests publications are almost or completely absent, with the exception of two systems. The Xpert Xpress has been thoroughly investigated and good performance has been reported, whereas ID NOW is also well-represented in literature, but has relatively low sensitivity. The Author(s). Published by Elsevier B.V. 2022-09 2022-05-21 /pmc/articles/PMC9122839/ /pubmed/35619623 http://dx.doi.org/10.1016/j.biosx.2022.100158 Text en © 2022 The Author(s) Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Bruijns, Brigitte Folkertsma, Laura Tiggelaar, Roald FDA authorized molecular point-of-care SARS-CoV-2 tests: A critical review on principles, systems and clinical performances |
title | FDA authorized molecular point-of-care SARS-CoV-2 tests: A critical review on principles, systems and clinical performances |
title_full | FDA authorized molecular point-of-care SARS-CoV-2 tests: A critical review on principles, systems and clinical performances |
title_fullStr | FDA authorized molecular point-of-care SARS-CoV-2 tests: A critical review on principles, systems and clinical performances |
title_full_unstemmed | FDA authorized molecular point-of-care SARS-CoV-2 tests: A critical review on principles, systems and clinical performances |
title_short | FDA authorized molecular point-of-care SARS-CoV-2 tests: A critical review on principles, systems and clinical performances |
title_sort | fda authorized molecular point-of-care sars-cov-2 tests: a critical review on principles, systems and clinical performances |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9122839/ https://www.ncbi.nlm.nih.gov/pubmed/35619623 http://dx.doi.org/10.1016/j.biosx.2022.100158 |
work_keys_str_mv | AT bruijnsbrigitte fdaauthorizedmolecularpointofcaresarscov2testsacriticalreviewonprinciplessystemsandclinicalperformances AT folkertsmalaura fdaauthorizedmolecularpointofcaresarscov2testsacriticalreviewonprinciplessystemsandclinicalperformances AT tiggelaarroald fdaauthorizedmolecularpointofcaresarscov2testsacriticalreviewonprinciplessystemsandclinicalperformances |